Head and Neck Cancer
1,615
238
314
822
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
256 trials with published results (16%)
Research Maturity
822 completed trials (51% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
10.4%
168 terminated out of 1615 trials
83.0%
-3.6% vs benchmark
8%
129 trials in Phase 3/4
31%
256 of 822 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 822 completed trials
Clinical Trials (1615)
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Mental Health App for Cancer Survivors Study
Distance-Based Exercise to Preserve Function and Prevent Disability
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population
Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
Understanding the Role of MyCareGorithm as a Visual Digital Platforms in Cancer Treatment Education and Patient Comprehension of Oncology Treatment Plans
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Pilot Study of Management of Facial Paralysis in the Oncologic Patient: Nerve Transfer Techniques to Improve Facial Function and Quality of Life
DESTINY-PANTUMOUR04
Resistance Training and Creatine Supplementation for Head and Neck Cancer
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)